Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cancer antigen helper peptide

An antigen and auxiliary technology, applied in the direction of cancer antigen components, tumor-specific antigens, vertebrate antigen components, etc.

Active Publication Date: 2012-11-28
INT INST OF CANCER IMMUNOLOGY INC
View PDF6 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Prior to this, studies have strongly demonstrated that WT1-specific CTLs can be induced not only in mice but also in humans, and that such CTLs have cytotoxic activity against tumor cells that highly express the WT1 gene, but not against endogenous tumor cells. Normal cells endogenously expressing the WT1 gene have no cytotoxic activity (Non-Patent Documents 7 and 10-14)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cancer antigen helper peptide
  • Cancer antigen helper peptide
  • Cancer antigen helper peptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0134] Selection of candidate WT1 peptides that bind to MHC class II molecules

[0135] To search for peptide sequences that bind to MHC class II molecules, the method shown by Rammensee et al. (Rammensee et al., Immunogenetics 41:178-228, 1995) was used. Specifically, the selection was made using the program described in the right-hand column of the table and the rule of Rammensee et al. By this method, the WT1 35 Peptides were restricted to the peptide sequences shown in Tables 1 and 2, the WT1 86 Peptides were restricted to the peptide sequences shown in Tables 3 and 4, and the WT1 294 Peptides were restricted to the peptide sequences shown in Table 5 and Table 6. The left-hand column in Tables 1-6 indicates "suitability" as a candidate peptide sequence. The larger the number of "○", the higher the suitability for the rule of Rammensee et al. No mark indicates poor fit. Similarly, the amino acid groups in brackets in the column of "candidate peptide sequences bindin...

Embodiment 2

[0161] Determination of WT1-specific cytotoxic T cells (CTL)

[0162] Mice were treated with only WT1 126 Peptide (MHC class I), WT1 126 Peptide (MHC class I) + WT1 35 Peptide (MHC class II), WT1 126 Peptide (MHC class I) + WT1 86 Peptide (MHC class II) or WT1 126 Peptide (MHC class I) + WT1 294 Peptide (MHC class II) was immunized three times, and spleen cells of mice were prepared. Then, splenocytes were treated with WT1 126 Peptide (MHC class I) stimulated once in vitro, on the 6th day, use WT1 126 RMAS cells pulsed with peptide (MHC class I) were used as target cells, and cytotoxic activity was measured. Unused WT1 126 Peptide (MHC class I) pulsed RMAS cells were used as control target cells. Therefore, with only WT1 126 Peptide (MHCI class I) immunized mouse splenocytes compared with WT1 126 The splenocytes of mice immunized with peptide (MHC class I) + WT1 helper peptide (MHC class II) more strongly induced WT1-specific cytotoxic T cells ( Figure 5 ). Th...

Embodiment 3

[0164] tumor implantation experiments

[0165] The C1498 leukemia cells expressing WT1 were divided into 2.5×10 5 The ratio of cells / mouse was subcutaneously implanted into mice, and 50 μg / mouse of WT1 was injected once a week for 3 times from one week after implantation 35 The helper peptide was administered intradermally with Freund's incomplete adjuvant ( Image 6 ). As a control, WT1 was replaced with saline 35 The helper peptide was administered intradermally with Freund's incomplete adjuvant. The size of subcutaneous tumors was measured over time, and disease-free survival was calculated until day 29 after subcutaneous implantation. As a result, tumors enlarged in all mice in the control group, whereas in WT1 35 In the helper peptide (MHC class II) immunization group, tumor proliferation was completely inhibited in 4 out of 10 mice ( Figure 7 ). Similarly, WT1 35 A significant difference was seen between the auxiliary peptide immunization group and the control...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are: a WT1 peptide which comprises an amino acid sequence composed of contiguous amino acid residues derived from a WT1 protein and can bind to an MHC class-II molecule to induce a WT1-specific helper T cell; a pharmaceutical composition containing the peptide; and others.

Description

technical field [0001] The present invention relates to a WT1 helper peptide, a polynucleotide encoding the peptide, WT1-specific helper T cells induced by the peptide, and a pharmaceutical composition for treating / preventing cancer comprising them. This application claims priority from Japanese Patent Application No. 2009-105286 filed on April 23, 2009, the disclosure of which is incorporated herein by reference. Background technique [0002] WT1 gene (Wilms' tumor 1 gene) is a gene identified as a Wilms' tumor-inducing gene for childhood renal cancer (Non-Patent Documents 1 and 2), and is a transcriptional gene with a zinc finger structure factor. The WT1 gene was originally thought to be a cancer suppressor gene. However, subsequent studies have shown that the above-mentioned genes are more suitable as oncogenes for hematopoietic organ tumors and solid cancers (Non-Patent Documents 3-6). [0003] Since the WT1 gene is highly expressed in many malignancies, it has been ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K31/7088A61K38/00A61K48/00A61P35/00C07K14/82C12N5/07C12Q1/04C12Q1/06G01N33/68G01N33/53
CPCC07K14/4702A61K39/0011C07K14/4748G01N33/57438A61K38/00A61K39/00A61K2039/55566A61K48/00C07K14/82C07K16/32C12N5/0635C12N5/0636C12N5/0639C12N5/0645G01N33/68A61K39/001153C12N5/0634A61P1/04A61P1/16A61P11/00A61P13/08A61P13/10A61P15/00A61P17/00A61P19/00A61P35/00A61P35/02A61K38/17A61K38/177A61K38/1774C07K16/18C07K16/30G01N33/56966
Inventor 杉山治夫
Owner INT INST OF CANCER IMMUNOLOGY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com